OKYOOKYO Pharma Ltdvs its industry peers
A metric-by-metric comparison of OKYO Pharma Ltd against SIC 2836 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OKYOThis | $87M#5 | — | — | — | — | — | — | — | — | — | -47.2%#1 | — |
| MESO | $18.5B#1 | — | — | — | — | — | — | — | — | — | — | — |
| MOLN | $161M#4 | — | — | — | — | — | — | — | — | — | — | — |
| PROK | — | — | — | — | 1075.0%#1 | -12.7%#2 | -18477.8%#4 | — | — | — | — | — |
| QGEN | $9.2B#2 | 21.8x#1 | 2.4x#1 | 4.4x#1 | 5.7%#3 | 408.3%#1 | 22.3%#1 | 11.2%#1 | 8.8%#1 | 7#1 | — | 0.6%#1 |
| SCNI | $3.8B#3 | 68.2x#2 | 467.1x#2 | 2886.7x#2 | 99.2%#2 | -273.2%#4 | -575.3%#3 | -102.5%#2 | -110.5%#2 | — | — | — |
| SGMOQ | — | — | — | — | -31.6%#4 | -25.5%#3 | -306.5%#2 | — | — | — | — | — |
| SLBT | $3#6 | — | — | — | — | — | — | — | — | — | -68.5%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2836). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-08-04.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice